rare cancer
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumour
Phil Taylor
Daiichi Sankyo, FDA approval, rare cancer, rare disease
0 Comment
Market Access/ News/ News/ News/ Oncology/ Top stories
NICE recommends Pfizer’s Xalkori in rare lung cancer
Linda Banks
lung cancer, NSCLC, Pfizer, rare cancer, rare disease, Xalkori
0 Comment
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
News/ News/ Oncology/ R&D/ UK & Europe
Immunocore’s rare cancer treatment gains UK Promising Medicine designation
Andrew McConaghie
cancer, Immunocore, innovative medicine, Oncology, Promising Innovative Medicine, rare cancer
0 Comment
Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.